The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Lighting Up the Fire in the Microenvironment of Cold Tumors: A Major Challenge to Improve Cancer Immunotherapy
Open accessAbstract
Immunotherapy includes immune checkpoint inhibitors (ICI) such as antibodies targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or the programmed cell death protein/programmed death ligand 1 (PD-1/PD-L1) axis. Experimental and clinical evidence show that immunotherapy based on immune checkpoint inhibitors (ICI) provides long-term survival benefits to cancer patients in whom other conventional therapies have failed. However, only a minority of patients show high clinical benefits via the use of ICI alone. One of the major factors limiting the clinical benefits to ICI can be attributed to the lack of immune cell infiltration within the tumor microenvironment. Such tumors are classified as "cold/warm" or an immune "desert"; those displaying significant infiltration are considered "hot" or inflamed. This review will provide a brief summary of different tumor properties contributing to the establishment of cold tumors and describe major strategies that could reprogram non-inflamed cold tumors into inflamed hot tumors. More particularly, we will describe how targeting hypoxia can induce metabolic reprogramming that results in improving and extending the benefit of ICI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As noted above, based on their TME, tumors can be categorized into two general types: ‘hot’ tumors, distinguished by an immunosupportive TME and a positive response to immunotherapy, and ‘cold’ or non-immune reactive tumors exhibiting a poor response to immunotherapy and characterized by an immunosuppressive TME (Zhang et al., 2022; Benoit et al., 2023).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Benoit et al., 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“‘Hot’ tumors show enrichment in CD8+ lymphocytes and M1 TAMs, with low infiltration of MDSCs or CAFs, resulting in a more favorable response to immunotherapy.”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Benoit et al., 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, the TME of ‘cold’ tumors is defined by the presence of more Tregs than CD8+ lymphocytes and high infiltration of M2 TAMs, MDSCs, and CAFs (Benoit et al., 2023).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Benoit et al., 2023
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909353106 · Cited by 451 · cited 4×
“HIF-1 is composed of two subunits, HIF-1α and HIF-1β; both have basic helix–loop–helix domains and can form a heterodimer and bind to the promoter of target genes.”
BackgroundInfluentialRetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952 · cited 1×
“This activation is characterized by the expression of pattern recognition receptors (PRRs) and binding of pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs) [18].”
BackgroundCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · cited 2×
“The TGF-β blockade in combination with anti-PD-L1 treatment contributes to an increase in T cell infiltration and improvement in tumor regression in mouse models [41].”
BackgroundHypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645 · cited 2×
“HIF2α can also bind to HIF-1β, and it plays a role in vascularization, pulmonary development, and erythropoiesis [118].”
BackgroundChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“The CAR-T cell approach showed significant efficacy in acute lymphoid leukemia and lymphoma [114,115].”
BackgroundComprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409 · cited 1×
“Altered or warm tumors have low infiltration of immune cells, either in the tumor margin only (altered-excluded tumors) or in both areas (altered-immunosuppressed tumors) [7,8].”
BackgroundTumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230 · cited 1×
“TMB has been proposed as a biomarker of the response to anti-PD-1 therapy [12].”
BackgroundCar t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207 · cited 1×
“Three types of ACT have been developed: tumor-infiltrating lymphocytes (TILs), T cell receptor (TCR)-engineered T cells, and CAR-T cells [104].”
BackgroundTargeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172 · cited 1×
“Currently, targeting hypoxia, or more particularly HIF-1α, relies on developing hypoxia-activated prodrugs or small inhibitors targeting molecules involved in the survival of hypoxic cells [148].”
BackgroundMelanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · cited 1×
“In melanoma, tumor-intrinsic active β-catenin signaling has been associated with the absence of type-1 DCs and effector CD8+ T cells in addition to resistance to anti-PD-L1 and anti-CTLA-4 therapy [27].”
BackgroundImmune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709 · cited 2×
“Since CTLA-4 presents a higher affinity for CD80 and CD86 ligands than CD28, the expression of CTLA-4 will inhibit lymphocyte activation [3].”
BackgroundAdoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506 · cited 1×
“This strategy has been shown to induce complete and durable regressions in metastatic melanoma patients [105].”
BackgroundRadiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166 · cited 2×
“Emerging new data demonstrates that hypoxia is involved in the alteration of tumor metabolism and metabolites, pH regulation, and overexpression of several immune checkpoints including macrophage immune checkpoints CD47, PD-L1, and HLA-G [29,30,32,33].”
BackgroundSelf-citationRosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,140 · cited 1×
“Therefore, TILs only have benefits in a few cancer types—they have limited benefits (20% of reported objective response rate for metastatic melanoma) [106].”
BackgroundTGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851 · cited 1×
“For instance, transforming growth factor-β (TGF-β) contributes to the lack of T cell infiltration and low response to anti-PD-1/PD-L1 immunotherapy in metastatic urothelial cancer [41] and colon cancer metastasis [42].”
BackgroundMacrophages and metabolism in the tumor microenvironment
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., & Galluzzi, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.001 · Cited by 1,837 · cited 1×
“This results in a shift toward oxidative metabolism and increased glucose availability in the tumor microenvironment [137].”
BackgroundVEGF as a Key Mediator of Angiogenesis in Cancer
Carmeliet, P. (2005) · Oncology · doi:10.1159/000088478 · Cited by 1,768 · cited 1×
“These characteristics lead to generating more hypoxia and thus more VEGF production [123].”
BackgroundDewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0265 · Cited by 1,678 · cited 1×
“Briefly, in a breast carcinoma mouse model, dual treatment with fractioned radiotherapy and an anti-CTLA-4 antibody enhanced the abscopal effect [54], which refers to tumor regression outside the field of radiation due to an indirect systemic anti-tumoral effect induced by radiotherapy [55].”
BackgroundKochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595 · cited 1×
“The CAR-T cell approach showed significant efficacy in acute lymphoid leukemia and lymphoma [114,115].”
BackgroundLoss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539 · cited 1×
“Indeed, a loss of phosphatase and tensin homolog (PTEN) has been correlated with the expression of immunosuppressive cytokines and decreased T cell infiltration to the tumor microenvironment in addition to an increase in tumor resistance to immunotherapy [26].”
BackgroundHypoxia and the extracellular matrix: drivers of tumour metastasis
Gilkes, D. M., Semenza, G. L., & Wirtz, D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3726 · Cited by 1,520 · cited 1×
“HIF-1 is also responsible for the up-regulation of glucose transporter proteins (GLUTs) in cancer cells to promote glycolysis [127] and the induction of epithelial to mesenchymal transition (EMT) in several types of cancer, thus promoting tumor progression and metastasis [128,129].”
BackgroundSakaguchi, S., Sakaguchi, N., Shimizu, J., Yamazaki, S., Sakihama, T., Itoh, M., Kuniyasu, Y., Nomura, T., Toda, M., & Takahashi, T. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1820102.x · Cited by 1,505
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376 · cited 1×
“function of MDSCs by inducing the expression of VISTA on myeloid cells [136].”
BackgroundAutophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
Yamamoto, K., Venida, A., Yano, J., Biancur, D. E., Kakiuchi, M., Gupta, S., Sohn, A. S. W., Mukhopadhyay, S., Lin, E. Y., Parker, S. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2229-5 · Cited by 1,240 · cited 1×
“Genetic and pharmacological inhibition of autophagy was shown to improve anti-PD1 and anti-CTLA4 antibody-based immunotherapy [68].”
BackgroundChemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121 · cited 1×
“In melanoma, the chemokines CCL2, 3, 4, and 5 as well as CXCL9 and 10 were reported to induce effective T cell migration into the tumor microenvironment [39].”
BackgroundCold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,108 · cited 1×
“Altered or warm tumors have low infiltration of immune cells, either in the tumor margin only (altered-excluded tumors) or in both areas (altered-immunosuppressed tumors) [7,8].”
BackgroundNanoparticle‐Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy
Duan, X., Chan, C., & Lin, W. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201804882 · Cited by 1,033
Jongbloed, S. L., Kassianos, A. J., McDonald, K. J., Clark, G. J., Ju, X., Angel, C. E., Chen, C.-J. J., Dunbar, P. R., Wadley, R. B., Jeet, V., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092140 · Cited by 1,027 · cited 1×
“Such stimulation regulates the expression of co-activator receptors CD80 and CD86, which are present on T cells [19].”
BackgroundDemaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., & Formenti, S. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.728.11.2 · Cited by 1,022
Neoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020 · cited 2×
“However, the immune system cannot recognize the majority of tumor antigens because they are considered to be self-proteins [10].”
BackgroundHypoxia-Inducible Factors: Master Regulators of Cancer Progression
Schito, L., & Semenza, G. L. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.016 · Cited by 962 · cited 2×
“Hypoxia influences tumor immune escape through four different aspects: (i) regulation of signal transduction pathways, (ii) suppression of immune effector cells, (iii) recruitment of immunosuppressive cells and upregulation of inhibitory immune checkpoints, and (iv) activation of autophagy [122].”
BackgroundHypoxia-Inducible Factor 1 (HIF-1) Pathway
Semenza, G. L. (2007) · Science's STKE · doi:10.1126/stke.4072007cm8 · Cited by 945 · cited 2×
“In the nucleus, HIF-1α forms a dimer with the subunit HIF-1β, and the heterodimer binds to the hypoxia response elements (HRE) m tif in the promoter of different targe genes to ac vate their transcription [120,121] (Figure 3).”
BackgroundSpring, L. M., Fell, G., Arfe, A., Sharma, C., Greenup, R., Reynolds, K. L., Smith, B. L., Alexander, B., Moy, B., Isakoff, S. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3492 · Cited by 938 · cited 1×
“Another study showed a correlation between adjuvant chemotherapy and decreased regulatory Treg infiltration in breast cancer; there was also an increase in cytotoxic T cell infiltration [45].”
BackgroundCancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
Liu, T., Han, C., Wang, S., Fang, P., Ma, Z., Xu, L., & Yin, R. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0770-1 · Cited by 860 · cited 1×
“In contrast to normal fibroblasts which are activated following the wound healing process, inflammation, or fibrosis, CAFs are constitutively-activated stromal cells producing ECM, growth factors, and cytokines to promote angiogenesis and recruit immune suppressive cells [22].”
BackgroundA mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells
Barsoum, I. B., Smallwood, C. A., Siemens, D. R., & Graham, C. H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0992 · Cited by 767 · cited 1×
“Hypoxia is responsible for tumor escape from immune surveillance [35,140].”
BackgroundMaleki Vareki, S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0479-7 · Cited by 569
Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K
Courtnay, R., Ngo, D. C., Malik, N., Ververis, K., Tortorella, S. M., & Karagiannis, T. C. (2015) · Molecular Biology Reports · doi:10.1007/s11033-015-3858-x · Cited by 567 · cited 1×
“HIF-1 is also responsible for the up-regulation of glucose transporter proteins (GLUTs) in cancer cells to promote glycolysis [127] and the induction of epithelial to mesenchymal transition (EMT) in several types of cancer, thus promoting tumor progression and metastasis [128,129].”
BackgroundAn HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
Palazon, A., Tyrakis, P. A., Macias, D., Veliça, P., Rundqvist, H., Fitzpatrick, S., Vojnovic, N., Phan, A. T., Loman, N., Hedenfalk, I., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.003 · Cited by 521 · cited 3×
“In the nucleus, HIF-1α forms a dimer with the subunit HIF-1β, and the heterodimer binds to the hypoxia response elements (HRE) m tif in the promoter of different targe genes to ac vate their transcription [120,121] (Figure 3).”
BackgroundSemenza, G. L. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.08.006 · Cited by 483
Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
Leko, V., & Rosenberg, S. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.013 · Cited by 449 · cited 1×
“” This could also cause unintentional cross-reactivity expressing normal proteins with a similar structure called “off-target toxicity” [11].”
BackgroundZhang, H., Lu, H., Xiang, L., Bullen, J. W., Zhang, C., Samanta, D., Gilkes, D. M., He, J., & Semenza, G. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520032112 · Cited by 420 · cited 1×
“Emerging new data demonstrates that hypoxia is involved in the alteration of tumor metabolism and metabolites, pH regulation, and overexpression of several immune checkpoints including macrophage immune checkpoints CD47, PD-L1, and HLA-G [29,30,32,33].”
BackgroundNoman, M. Z., Hasmim, M., Messai, Y., Terry, S., Kieda, C., Janji, B., & Chouaib, S. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00207.2015 · Cited by 400 · cited 1×
“Emerging new data demonstrates that hypoxia is involved in the alteration of tumor metabolism and metabolites, pH regulation, and overexpression of several immune checkpoints including macrophage immune checkpoints CD47, PD-L1, and HLA-G [29,30,32,33].”
BackgroundJayaprakash, P., Ai, M., Liu, A., Budhani, P., Bartkowiak, T., Sheng, J., Ager, C., Nicholas, C., Jaiswal, A. R., Sun, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96268 · Cited by 399 · cited 1×
“This effect was associated with a decrease in MDSCs in the tumor microenvironment, and a decrease in intra-tumoral hypoxia [143].”
BackgroundmRNA therapeutics in cancer immunotherapy
Beck, J. D., Reidenbach, D., Salomon, N., Sahin, U., Türeci, Ö., Vormehr, M., & Kranz, L. M. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01348-0 · Cited by 385 · cited 2×
“This vaccine has been reported to cause the induction of CD8+ T cell infiltration in a CXCL10 manner and upregulation of immune inhibitory checkpoints such as CTLA-4 [86], thus showing that anti-cancer vaccines are interesting leads and require further investigation [82].”
BackgroundSamson, A., Scott, K. J., Taggart, D., West, E. J., Wilson, E., Nuovo, G. J., Thomson, S., Corns, R., Mathew, R. K., Fuller, M. J., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7577 · Cited by 373 · cited 1×
“For highgrade gliomas, an intravenous infusion of the oncolytic human Orthoreovirus in patients could increase the cytotoxic T cell infiltration within the tumors, IFN gene expression, and expression of PD-1 and PD-L1, thus suggesting that the combination of this reovirus with PD-1/PD-L1 blockade could lead to signifi…”
BackgroundBerchem, G., Noman, M. Z., Bosseler, M., Paggetti, J., Baconnais, S., Le cam, E., Nanbakhsh, A., Moussay, E., Mami-Chouaib, F., Janji, B., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1062968 · Cited by 317
Bourgeois-Daigneault, M.-C., Roy, D. G., Aitken, A. S., El Sayes, N., Martin, N. T., Varette, O., Falls, T., St-Germain, L. E., Pelin, A., Lichty, B. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao1641 · Cited by 293
Hypoxia induced EMT: A review on the mechanism of tumor progression and metastasis in OSCC
Joseph, J. P., Harishankar, M. K., Pillai, A. A., & Devi, A. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.03.004 · Cited by 282 · cited 1×
“HIF-1 is also responsible for the up-regulation of glucose transporter proteins (GLUTs) in cancer cells to promote glycolysis [127] and the induction of epithelial to mesenchymal transition (EMT) in several types of cancer, thus promoting tumor progression and metastasis [128,129].”
BackgroundHypoxia-Driven Immune Escape in the Tumor Microenvironment
Vito, A., El-Sayes, N., & Mossman, K. (2020) · Cells · doi:10.3390/cells9040992 · Cited by 270 · cited 1×
“Hypoxia is responsible for tumor escape from immune surveillance [35,140].”
BackgroundCancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
Shafer, P., Kelly, L. M., & Hoyos, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835762 · Cited by 270 · cited 1×
“Such a strategy deflects T cell specificity to recognize specific antigens in the context of HLA presentation in any subcellular compartment [109].”
BackgroundNoman, M. Z., Janji, B., Kaminska, B., Van Moer, K., Pierson, S., Przanowski, P., Buart, S., Berchem, G., Romero, P., Mami-Chouaib, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1094 · Cited by 256 · cited 1×
“Interestingly, blocking hypoxia-induced autophagy restored cytotoxic T cell activity and promoted tumor regression [139].”
BackgroundSelf-citationNoman, M. Z., Parpal, S., Van Moer, K., Xiao, M., Yu, Y., Arakelian, T., Viklund, J., De Milito, A., Hasmim, M., Andersson, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aax7881 · Cited by 255
Self-citationWatanabe, K., Kuramitsu, S., Posey, A. D., & June, C. H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02486 · Cited by 242
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
Phillips, R. M. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2920-7 · Cited by 238 · cited 1×
“The drug has shown relevant potential when used in combination with cytotoxic drugs, targeted therapy, or radiotherapy [144].”
BackgroundVISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy
Huang, X., Zhang, X., Li, E., Zhang, G., Wang, X., Tang, T., Bai, X., & Liang, T. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00917-y · Cited by 231 · cited 1×
“Targeting of VISTA by antibody or genetic ablation under hypoxia decreased MDSC-mediated T cell suppression, thus suggesting that combination approaches targeting both VISTA and hypoxia could reverse the immunosuppressive antitumor immunity, and thus improve immunotherapy [141].”
BackgroundMgrditchian, T., Arakelian, T., Paggetti, J., Noman, M. Z., Viry, E., Moussay, E., Van Moer, K., Kreis, S., Guerin, C., Buart, S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703921114 · Cited by 226 · cited 1×
“Emerging preclinical data show that targeting the autophagy-related gene Beclin-1 inhibits tumor growth and induces the infiltration of functional NK cells into the microenvironment of melanoma tumors in a CCL5-dependent manner [63,64].”
BackgroundSelf-citationHayes, C., Donohoe, C. L., Davern, M., & Donlon, N. E. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.021 · Cited by 213 · cited 1×
“Lactate also promotes the development of immunosuppressive Tregs and immune cell exhaustion due to the switch in metabolic activity and the lack of nutrients within the tumor microenvironment [131].”
BackgroundNoman, M. Z., Hasmim, M., Lequeux, A., Xiao, M., Duhem, C., Chouaib, S., Berchem, G., & Janji, B. (2019) · Cells · doi:10.3390/cells8091083 · Cited by 212
Dallavalasa, S., Beeraka, N. M., Basavaraju, C. G., Tulimilli, S. V., Sadhu, S. P., Rajesh, K., Aliev, G., & Madhunapantula, S. V. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210720143721 · Cited by 210 · cited 1×
“The pro-tumoral M2 macrophages promote angiogenesis, metastasis, as well as key signaling pathways involved in treatment resistance [21].”
BackgroundHojo, S., Koizumi, K., Tsuneyama, K., Arita, Y., Cui, Z., Shinohara, K., Minami, T., Hashimoto, I., Nakayama, T., Sakurai, H., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3424 · Cited by 201 · cited 1×
“Higher levels of CXCL16 have been associated with increased tumor-infiltrating lymphocytes (TILs) and better prognosis in colorectal cancer [38].”
BackgroundLi, Y., Patel, S. P., Roszik, J., & Qin, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01591 · Cited by 195
Newman, J. H., Chesson, C. B., Herzog, N. L., Bommareddy, P. K., Aspromonte, S. M., Pepe, R., Estupinian, R., Aboelatta, M. M., Buddhadev, S., Tarabichi, S., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904022116 · Cited by 187 · cited 1×
“In addition, the neoadjuvant flu shot injection could improve tumor responses to anti-PD-L1 immune checkpoint blockade compared to anti-PD-1 alone [78].”
BackgroundYang, S., Wu, C., XIONG, Z.-F., & Fang, X. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3689 · Cited by 185 · cited 4×
“A high expression of HIF-1α and/or HIF-2α has been associated with an increased risk of Cells 2023, 12, 1787 13 of 21 mortality in more than 10 different types of cancer [118].”
BackgroundInfluentialZhou, T., Liang, X., Wang, P., Hu, Y., Qi, Y., Jin, Y., Du, Y., Fang, C., & Tian, J. (2020) · ACS Nano · doi:10.1021/acsnano.0c01453 · Cited by 174 · cited 2×
“Nanoparticles are also considered to target hypoxia in glioblastoma [56,99,100,146].”
BackgroundImmune Response Regulation in the Tumor Microenvironment by Hypoxia
Labiano, S., Palazón, A., & Melero, I. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.009 · Cited by 168 · cited 1×
“In Tregs, hypoxia induces the secretion of the chemokine CCL28, which is responsible for their recruitment to the tumor microenvironment [135].”
BackgroundParra, E. R., Villalobos, P., Behrens, C., Jiang, M., Pataer, A., Swisher, S. G., William, W. N., Zhang, J., Lee, J., Cascone, T., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0368-0 · Cited by 167 · cited 1×
“Neoadjuvant chemotherapy had the same effects in non-small cell lung carcinoma (NSCLC) in which the number of tumor-associated immune cells was higher in tumors from patients receiving neoadjuvant chemotherapy compared to tumors from untreated patients [46].”
ResultKoller, K. M., Mackley, H. B., Liu, J., Wagner, H., Talamo, G., Schell, T. D., Pameijer, C., Neves, R. I., Anderson, B. E., Kokolus, K. M., et al. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1264543 · Cited by 164 · cited 1×
“In advanced melanoma, combining radiation therapy with ipilimumab resulted in improved patient survival and complete response rates [60].”
BackgroundMelaiu, O., Chierici, M., Lucarini, V., Jurman, G., Conti, L. A., De Vito, R., Boldrini, R., Cifaldi, L., Castellano, A., Furlanello, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19781-y · Cited by 163
Bevers, S., Kooijmans, S. A. A., van de Velde, E., Evers, M. J. W., Seghers, S., Gitz-Francois, J. J., van Kronenburg, N. C. H., Fens, M. H. A. M., Mastrobattista, E., Hassler, L., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.07.007 · Cited by 161 · cited 1×
“Lipid-based nanoparticles delivering mRNA could stimulate a T cell response without conferring changes in the spleen and liver of non-human primates [80].”
BackgroundSalter, A. I., Rajan, A., Kennedy, J. J., Ivey, R. G., Shelby, S. A., Leung, I., Templeton, M. L., Muhunthan, V., Voillet, V., Sommermeyer, D., et al. (2021) · Science Signaling · doi:10.1126/scisignal.abe2606 · Cited by 160
Alghamri, M. S., Banerjee, K., Mujeeb, A., Mauser, A., Taher, A. W., Thalla, R., McClellan, B. L., Varela, M. L., Stamatovic, S. M., Martínez-Revollar, G., et al. (2022) · ACS Nano · doi:10.1021/acsnano.1c07492 · Cited by 160 · cited 2×
“Nanoparticles are also considered to target hypoxia in glioblastoma [56,99,100,146].”
BackgroundLussier, D. M., Alspach, E., Ward, J. P., Miceli, A. P., Runci, D., White, J. M., Mpoy, C., Arthur, C. D., Kohlmiller, H. N., Jacks, T., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102611118 · Cited by 152 · cited 1×
“In addition, radiation induces the expression of mutant proteins and potentially mutant neoantigens, which can generate a CD8+ T cell response [52].”
Backgroundvan Cruijsen, H., van der Veldt, A. A. M., Vroling, L., Oosterhoff, D., Broxterman, H. J., Scheper, R. J., Giaccone, G., Haanen, J. B. A. G., van den Eertwegh, A. J. M., Boven, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0656 · Cited by 148
Autophagy modulation: a target for cancer treatment development
Duffy, A. P., Le, J., Sausville, E. A., & Emadi, A. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2637-z · Cited by 143 · cited 1×
“It has been shown that chloroquine had a synergistic effect when combined with anti-PD-1 and anti-CTLA-4 antibodies in mouse models of pancreatic cancer [69].”
BackgroundHepatic Tumor Microenvironments and Effects on NK Cell Phenotype and Function
Fernández, J. P., Luddy, K. A., Harmon, C., & O’Farrelly, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174131 · Cited by 142
PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
Hirsch, L., Zitvogel, L., Eggermont, A. M. M., & Marabelle, A. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0294-4 · Cited by 136 · cited 1×
“However, the response to immunotherapy is relatively heterogeneous according to the cancer type, and the benefits remain low for most patients [4].”
BackgroundTCR-T Immunotherapy: The Challenges and Solutions
Liu, Y., Yan, X., Zhang, F., Zhang, X., Tang, F., Han, Z., & Li, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.794183 · Cited by 130 · cited 6×
“PD-1 inhibits T cell activation by targeting the signaling of the TCR and CD28 ([9]), and thus, it would be interesting to evaluate the potential of the combination of anti-PD-1 and TCR-T cells therapy.”
BackgroundInfluentialLequeux, A., Noman, M. Z., Xiao, M., Van Moer, K., Hasmim, M., Benoit, A., Bosseler, M., Viry, E., Arakelian, T., Berchem, G., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01846-x · Cited by 129 · cited 3×
“Strategies are being developed to increase the secretion of pro-inflammatory chemokines and improve the infiltration of immune cells in the tumor such as targeting HIF-1α, which resulted in an increase in the pro-inflammatory chemokine CCL5 and an increase in the infiltration of CD4+ and CD8+ T cells as well as NK cel…”
BackgroundResultSelf-citationSevenich, L. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00163 · Cited by 127
Yoshimoto, Y., Suzuki, Y., Mimura, K., Ando, K., Oike, T., Sato, H., Okonogi, N., Maruyama, T., Izawa, S., Noda, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092572 · Cited by 126 · cited 1×
“In a Lewis lung carcinoma mouse model, the use of an anti-CTLA-4 antibody led to an enhancement of the anti-tumor activity of irradiation by delaying tumor growth and prolonging mice survival [58].”
BackgroundLiu, S., Liu, J., Li, H., Mao, K., Wang, H., Meng, X., Wang, J., Wu, C., Chen, H., Wang, X., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121645 · Cited by 122 · cited 1×
“Nanoparticles are also considered to target hypoxia in glioblastoma [56,99,100,146].”
BackgroundPelekanou, V., Carvajal‐Hausdorf, D., Altan, M., Wasserman, B. E., Carvajal-Hausdorf, C., Wimberly, H., Brown, J. R., Lannin, D. R., Pusztai, L., & Rimm, D. L. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0884-8 · Cited by 120 · cited 1×
“could increase the number of tumor-infiltrating lymphocytes (TILs) within the tumor and decrease PD-L1 expression in residual breast cancer tissues [44].”
BackgroundSethumadhavan, S., Silva, M., Philbrook, P., Nguyen, T., Hatfield, S. M., Ohta, A., & Sitkovsky, M. V. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187314 · Cited by 119 · cited 1×
“HIF-1 has a negative effect on MHC-I expression, thus limiting tumor cell recognition by T cells [132,133].”
BackgroundLequeux, A., Noman, M. Z., Xiao, M., Sauvage, D., Van Moer, K., Viry, E., Bocci, I., Hasmim, M., Bosseler, M., Berchem, G., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.021 · Cited by 117 · cited 1×
“Emerging new data demonstrates that hypoxia is involved in the alteration of tumor metabolism and metabolites, pH regulation, and overexpression of several immune checkpoints including macrophage immune checkpoints CD47, PD-L1, and HLA-G [29,30,32,33].”
BackgroundSelf-citationAbscopal effect of radiation in papillary adenocarcinoma
Ehlers, G., & Fridman, M. (1973) · British Journal of Radiology · doi:10.1259/0007-1285-46-543-220 · Cited by 116 · cited 1×
“Briefly, in a breast carcinoma mouse model, dual treatment with fractioned radiotherapy and an anti-CTLA-4 antibody enhanced the abscopal effect [54], which refers to tumor regression outside the field of radiation due to an indirect systemic anti-tumoral effect induced by radiotherapy [55].”
BackgroundWang, T., Zhang, H., Qiu, W., Han, Y., Liu, H., & Li, Z. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.12.029 · Cited by 110 · cited 1×
“The modulation of the immunosuppressive microenvironment with the inhibition of IDO1 and JQ1, a drug decreasing the expression of PD-L1 by tumor cells, improved the immunotherapy treatment of GBM in mice [101].”
BackgroundCD4+ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment
Lei, X., Khatri, I., de Wit, T., de Rink, I., Nieuwland, M., Kerkhoven, R. M., van Eenennaam, H., Sun, C., Garg, A. D., Borst, J. G., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35615-5 · Cited by 109 · cited 3×
“Although each subtype of APC is responsible for different functions in the immune response, the type-1 DCs (cDC1s) are the most important for the anti-tumor immune response because they are responsible for inducing anti-tumor CD8 T cell responses after the presentation of tumor antigens via the class I major histocomp…”
BackgroundInfluentialAlissafi, T., Hatzioannou, A., Legaki, A. I., Varveri, A., & Verginis, P. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102310 · Cited by 106 · cited 1×
“Tregs are also associated with cancer progression, invasion, and metastasis; they are valuable targets in the treatment of cancer [24].”
BackgroundImmunoliposomes in clinical oncology: State of the art and future perspectives
Merino, M., Zalba, S., & Garrido, M. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.015 · Cited by 105 · cited 1×
“The emergence of immunoliposomes facilitate the conjugation of monoclonal antibodies or derivatives [94] with interesting results.”
BackgroundMyeloid‐derived suppressor cells: Roles in the tumor microenvironment and tumor radiotherapy
Yin, Z., Li, C., Wang, J., & Xue, L. (2018) · International Journal of Cancer · doi:10.1002/ijc.31744 · Cited by 104 · cited 9×
“MDSCs promote the proliferation and activation of Tregs [25].”
BackgroundInfluentialJu, F., Luo, Y., Lin, C., Jia, X., Xu, Z., Tian, R., Lin, Y., Zhao, M., Chang, Y., Huang, X., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004762 · Cited by 90 · cited 1×
“Interestingly, the development of an in situ tumor vaccine expressing anti-CD47 antibodies resulted in tumor growth suppression, stronger long-term survival, and increased tumor-infiltrating lymphocytes in melanoma, lymphoma, and breast cancer mouse models [85].”
BackgroundHypoxia-active nanoparticles used in tumor theranostic
Wang, Y., Shang, W., Niu, M., Tian, J., & Xu, K. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s196959 · Cited by 87 · cited 1×
“They can be used to boost the efficiency of different treatments such as chemotherapy and radiotherapy [145].”
BackgroundThe Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
Li, Y., Zhao, L., & Li, X.-F. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.636892 · Cited by 75 · cited 2×
“The activation of TH302 occurs under hypoxia based on the reduction in free radical anions, leading to the release of bromo-iso-phosphoramide mustard (Br-IPM) or its stable downstream product, isophosphoramide mustard (IPM) [142].”
BackgroundRébé, C., & Ghiringhelli, F. (2015) · Future Oncology · doi:10.2217/fon.15.198 · Cited by 72
Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy
Borst, J. G., Busselaar, J., Bosma, D. M. T., & OSSENDORP, F. A. (2021) · European Journal of Immunology · doi:10.1002/eji.202048994 · Cited by 69 · cited 1×
“In addition, cDC1s are important in the response to PD-L1 therapy [15], and patient survival has been positively correlated with the abundance of tumor-infiltrating cDC1, making cDC1 a key factor in the anti-tumor response [15–17].”
BackgroundmRNA-Based Therapeutics in Cancer Treatment
Sun, H., Zhang, Y., Wang, G., Yang, W., & Xu, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020622 · Cited by 68 · cited 1×
“The IVT mRNAs are delivered by lipid nanoparticles, thus allowing recipient cells to produce many copies of the encoded proteins that can stimulate potent immune responses [81].”
BackgroundAn Injectable Hydrogel to Modulate T Cells for Cancer Immunotherapy
Zhang, D., Li, Q., Chen, X., Nie, X., Xue, F., Xu, W., & Luan, Y. (2022) · Small · doi:10.1002/smll.202202663 · Cited by 65 · cited 1×
“This can be achieved by designing an injectable hydrogel that triggers the immune response and mitochondrial biogenesis of T cells, while enhancing MHC I expression and lowering T cell exhaustion [91].”
BackgroundYang, J., & Zhang, C. (2020) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1612 · Cited by 63
A Century of Radiation Therapy and Adaptive Immunity
Schaue, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00431 · Cited by 59 · cited 1×
“Several studies showed that radiotherapy can induce an immune response [50] even for primary and metastatic brain cancers that are located in an area lacking appropriate immune surveillance [51].”
BackgroundMerino, M., Lozano, T., Casares, N., Lana, H., Trocóniz, I. F., ten Hagen, T. L. M., Kochan, G. T., Berraondo, P., Zalba, S., & Garrido, M. J. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00846-z · Cited by 57 · cited 1×
“A significant tumor regression of the melanoma murine model was observed by using targeted immunoliposomes containing doxorubicin and antibodies targeting PD-L1 [95].”
Backgroundvon Euw, E. M., Barrio, M. M., Furman, D., Bianchini, M., Levy, E. M., Yee, C., Li, Y., Wainstok, R., & Mordoh, J. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-19 · Cited by 56
Wang, Y., Wang, Y., Pan, J., Gan, L., & Xue, J. (2023) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2023.109689 · Cited by 55 · cited 1×
“Furthermore, radiotherapy induces ferroptosis, necroptosis, and pyroptosis, which can stimulate a post-radiation immune response [53].”
BackgroundThe regulation of immune checkpoints by the hypoxic tumor microenvironment
Hu, M., Li, Y., Lu, Y., Wang, M., Li, Y., Wang, C., Li, Q., & Zhao, H. (2021) · PeerJ · doi:10.7717/peerj.11306 · Cited by 51 · cited 1×
“Finally, hypoxia triggers the activation of autophagy, thus impairing tumor cell susceptibility to NK and CTL-mediated killing [134].”
BackgroundElastic Nanovaccine Enhances Dendritic Cell‐Mediated Tumor Immunotherapy
Li, Q., Teng, Z., Tao, J., Shi, W., Yang, G., Zhang, Y., Su, X., Chen, L., Xiu, W., Yuwen, L., et al. (2022) · Small · doi:10.1002/smll.202201108 · Cited by 51 · cited 1×
“The combination of this nanovaccine with anti-PD-L1-blocking antibodies resulted in an enhanced therapeutic effect of anti-PD-L1 [84].”
BackgroundRegulation of Chemokine Expression in the Tumor Microenvironment
Gorbachev, A. V., & Fairchild, R. L. (2014) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2014010062 · Cited by 50 · cited 1×
“CCL19 and 21 can promote the recruitment of DCs into T cell priming sites, thus leading to T cell activation [37].”
BackgroundHagihara, K., Chan, S. E., Zhang, L., Oh, D. Y., Wei, X. X., Simko, J., & Fong, L. H. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1486953 · Cited by 49 · cited 1×
“This vaccine has been reported to cause the induction of CD8+ T cell infiltration in a CXCL10 manner and upregulation of immune inhibitory checkpoints such as CTLA-4 [86], thus showing that anti-cancer vaccines are interesting leads and require further investigation [82].”
BackgroundYin, H., Guo, W., Sun, X., Li, R., Feng, C., & Tan, Y. (2020) · Journal of Immunology Research · doi:10.1155/2020/8345235 · Cited by 48 · cited 1×
“The results show that the combination therapy of TILs and anti-PD1 significantly improves the prognosis of metastatic cervical cancer [108].”
BackgroundJanji, B., Hasmim, M., Parpal, S., Milito, A. D., Berchem, G., & Noman, M. Z. (2020) · Autophagy · doi:10.1080/15548627.2020.1815439 · Cited by 48
Targeting Cytoprotective Autophagy to Enhance Anticancer Therapies
Xiao, M., Benoit, A., Hasmim, M., Duhem, C., Vogin, G., Berchem, G., Noman, M. Z., & Janji, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.626309 · Cited by 48 · cited 1×
“Hypoxia can induce cytoprotective autophagy via the expression of BNIP/BNIP3L, leading to the dissociation of the Bcl-2/Beclin-1 complex to activate autophagy (reviewed in [138]).”
BackgroundT-Cell Receptor–Based Immunotherapy for Hematologic Malignancies
Biernacki, M. A., Brault, M., & Bleakley, M. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000378 · Cited by 47 · cited 1×
“They had good potential for colorectal cancer and leukemia treatment [111,112].”
BackgroundOncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice
Shoaf, M. L., & Desjardins, A. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01256-1 · Cited by 44
Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles
Rodallec, A., Sicard, G., Fanciullino, R., Benzekry, S., Lacarelle, B., Milano, G. A., & Ciccolini, J. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1540588 · Cited by 41 · cited 1×
“Nanoparticle-based therapy has been proposed as a strategy to increase the neo-antigen burden, modulate the tumor microenvironment, and trigger the antitumor immune response with the ultimate aim of improving immunotherapy [87].”
BackgroundFergusson, N., Adeel, K., Kekre, N. K., Atkins, H. L., & Hay, K. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1178403 · Cited by 40 · cited 1×
“Dual targeting with CD19 and CD22 CAR-T cells increased toxicity and improved the remission rates of acute lymphocytic leukemia and non-Hodgkin’s lymphoma patients [116].”
BackgroundGe, W., & Wu, W. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.106.07 · Cited by 39 · cited 1×
“TAMs are recruited to the tumor microenvironment and undergo polarization to generate macrophages displaying antitumoral phenotype (M1) or macrophages exhibiting a pro-tumoral phenotype (M2) [20].”
BackgroundAbadi, B., Yazdanpanah, N., Nokhodchi, A., & Rezaei, N. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114035 · Cited by 38 · cited 1×
“Nanoscience is also very promising for the treatment of glioblastoma (GBM), which is a very aggressive type of cancer with limited treatment options [97,98].”
BackgroundKudling, T. V., Clubb, J. H. A., Quixabeira, D. C. A., Santos, J. M., Havunen, R., Kononov, A., Heiniö, C., Cervera-Carrascón, V., Pakola, S. A., Basnet, S., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2096572 · Cited by 38 · cited 1×
“There is decreased tumor growth by up-regulating pro-inflammatory cytokines and inducing the activation and migration of CD4+ and CD8+ T cells [73].”
BackgroundMurthy, A., Gerber, S. A., Koch, C. J., & Lord, E. M. (2019) · ImmunoHorizons · doi:10.4049/immunohorizons.1900017 · Cited by 36 · cited 1×
“HIF-1 has a negative effect on MHC-I expression, thus limiting tumor cell recognition by T cells [132,133].”
BackgroundFerroptosis Inducer Improves the Efficacy of Oncolytic Virus-Mediated Cancer Immunotherapy
Liu, W., Chen, H., Zhu, Z., Liu, Z., Ma, C., Lee, Y. J., Bartlett, D. L., & Guo, Z. S. (2022) · Biomedicines · doi:10.3390/biomedicines10061425 · Cited by 36 · cited 2×
“There was an increase in the number and activity of tumor-infiltrating lymphocytes in hepatoma, colon, and ovarian cancer cells [72].”
BackgroundShi, M., Zhang, J., Wang, Y., Han, Y., Zhao, X., Hu, H., Qiao, M., & Chen, D. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.07.022 · Cited by 36 · cited 1×
“Another system of nanoparticles can inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) pathway and induce immunogenic cell death to enhance DC maturation, increase the number of CTLs, and decrease the number of Tregs in tumor tissues [96].”
BackgroundmRNA vaccination in breast cancer: current progress and future direction
Jiang, X., & Liu, Q. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04805-z · Cited by 35 · cited 1×
“In fact, several clinical trials are ongoing to evaluate the potential of mRNA vaccines for the treatment of a wide range of cancer types including breast cancer [82,83].”
BackgroundFiring up the cold tumors by targeting Vps34
Janji, B., Hasmim, M., Parpal, S., Berchem, G., & Noman, M. Z. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1809936 · Cited by 30
Self-citationAnti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy
Pol, J. G., & Kroemer, G. (2018) · Cell Research · doi:10.1038/s41422-018-0031-9 · Cited by 28 · cited 1×
“Certain types of immunotherapies display severe autoimmune side effects such as the CTLA-4-specific antibody ipilimumab despite the considerable efforts made to uncouple its toxicity and efficacy and potentiate its role as a depleting antibody of regulatory T cells [5].”
BackgroundShabani, L., Abbasi, M., Amini, M., Amani, A. M., & Vaez, A. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120316 · Cited by 27 · cited 1×
“Nanoscience is also very promising for the treatment of glioblastoma (GBM), which is a very aggressive type of cancer with limited treatment options [97,98].”
BackgroundValkema, M. J., Mostert, B., Lagarde, S. M., Wijnhoven, B. P. L., & van Lanschot, J. J. B. (2022) · Updates in Surgery · doi:10.1007/s13304-022-01327-0 · Cited by 27 · cited 1×
“For patients with non-metastatic and metastatic esophageal cancer, neoadjuvant chemoradiotherapy and immunotherapy have no effect on the survival benefits [48].”
BackgroundCombination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma
Foley, K. C., Nishimura, M. I., & Moore, T. V. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000436 · Cited by 26 · cited 1×
“These combinations showed an improved objective response in general, but also elevated toxicity with high doses of cytokines [107].”
BackgroundNisar, M., Paracha, R. Z., Adil, S., Qureshi, S. N., & Janjua, H. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.875188 · Cited by 26
Low-dose irradiation for reversing immunotherapy resistance: how to translate?
Ochoa-de-Olza, M., Bourhis, J., Coukos, G., & Herrera, F. G. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004939 · Cited by 25
Efficacy of T-Cell Receptor-Based Adoptive Cell Therapy in Cutaneous Melanoma: A Meta-Analysis
Yarza, R., Bover, M., Herrera, M., Rey-Cárdenas, M., Paz-Ares, L. G., Lopez-Martin, J. A., & Haanen, J. B. A. G. (2023) · The Oncologist · doi:10.1093/oncolo/oyad078 · Cited by 25 · cited 1×
“TCR-T cell therapy showed promising results and even significantly higher benefits compared to TILs for cutaneous melanoma [110].”
BackgroundQian, Y., Mao, J., Leng, X., Zhu, L., Xue, R., Jin, Z., Jiang, H., Liu, H., Zhang, F., Bi, X., et al. (2022) · Biomaterials Science · doi:10.1039/d2bm00611a · Cited by 24 · cited 1×
“The use of nanoparticles is also promising for other types of cold tumors such as colorectal cancer [102] and bladder cancer [103], where the delivery of specific drugs by nanoparticles was associated with a successful reprogramming of the tumor microenvironment with enhanced therapeutic efficacy.”
BackgroundStories From the Dendritic Cell Guardhouse
Hoober, J. K., Eggink, L. L., & Cote, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02880 · Cited by 21 · cited 1×
“In contrast, some receptors are called co-inhibitors, which will decrease the activation of effector cells such as programmed death protein 1 (PD-1) and its programmed death ligands PD-L1/PD-L2 [1].”
BackgroundWu, X., Wei, Y., Lin, R., Chen, P., Hong, Z., Zeng, R., Xu, Q., & Li, T. (2022) · Immunology · doi:10.1111/imm.13534 · Cited by 21 · cited 1×
“The use of nanoparticles is also promising for other types of cold tumors such as colorectal cancer [102] and bladder cancer [103], where the delivery of specific drugs by nanoparticles was associated with a successful reprogramming of the tumor microenvironment with enhanced therapeutic efficacy.”
BackgroundNoman, M. Z., Paggetti, J., Moussay, E., Berchem, G., & Janji, B. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1452583 · Cited by 20 · cited 1×
“Emerging preclinical data show that targeting the autophagy-related gene Beclin-1 inhibits tumor growth and induces the infiltration of functional NK cells into the microenvironment of melanoma tumors in a CCL5-dependent manner [63,64].”
BackgroundA PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model
Lin, Z., Zhang, Y., Cai, H., Zhou, F., Gao, H., Deng, L., & Li, R. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.06.002 · Cited by 20
Oncolytic Viruses as an Adjunct to Immune Checkpoint Inhibition
Ripp, J., Hentzen, S., & Saeed, A. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2705151 · Cited by 20 · cited 1×
“However, efforts are still needed to improve the drug delivery, bioavailability, and the cost of production of oncolytic viruses [77].”
BackgroundThe Promise of Targeting Hypoxia to Improve Cancer Immunotherapy: Mirage or Reality?
Janji, B., & Chouaïb, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.880810 · Cited by 19
Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer
Navarro-Ocón, A., Blaya-Cánovas, J. L., López-Tejada, A., Blancas, I., Sanchez-Martin, R. M., Garrido, M. J., Griñán‐Lisón, C., Calahorra, J., Cara, F. E., Ruiz‐Cabello, F., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030505 · Cited by 18
Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors
Li, Q., Oduro, P. K., Guo, R., Li, R., Leng, L., Kong, X., Wang, Q., & Yang, L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.921534 · Cited by 18 · cited 1×
“The use of oncolytic viruses is also a promising strategy for the most lethal malignancies that are not responding to classical treatment strategies such as pancreatic cancer [74], gastrointestinal malignant tumors [75], and glioblastoma [76].”
BackgroundWang, W., Li, L., Wu, S., Shen, J., Huang, C., Chen, Y., & Li, S. (2022) · Immunotherapy · doi:10.2217/imt-2021-0050 · Cited by 14 · cited 2×
“This was translated in clinical settings with a case report of a patient with small-cell lung carcinoma who was treated with a combination of radiation therapy and nivolumab [56].”
BackgroundMethodKatsuki, S., Takahashi, Y., Tamari, K., Minami, K., Takenaka, W., Ibuki, Y., Yamamoto, J., Tatekawa, S., Hayashi, K., Seo, Y., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271205 · Cited by 14 · cited 1×
“In murine osteosarcoma, radiotherapy could enhance antitumor efficacy of anti-PD-L1 treatment with a significant decrease in tumor growth and an improved overall survival via an increase in PD-1-positive and granzyme B-positive CD8+ T cells [57].”
BackgroundAdvances in adoptive cellular therapy for colorectal cancer: A narrative review
Yi, X., & Hu, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6196 · Cited by 14 · cited 1×
“They had good potential for colorectal cancer and leukemia treatment [111,112].”
BackgroundThe Emerging Role of IL-9 in the Anticancer Effects of Anti-PD-1 Therapy
Vinokurova, D., & Apétoh, L. (2023) · Biomolecules · doi:10.3390/biom13040670 · Cited by 14 · cited 1×
“Besides TGF-β, IFNγ, IL-2, and IL-9 also contribute to the efficacy of anti-PD-1 therapy [43].”
BackgroundSong, P., Han, X., Zheng, R., Yan, J., Wu, X., Wang, Y., & Zhang, H. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122002 · Cited by 13 · cited 1×
“Enhanced T cell infiltration and antigen presentation in B16-F10 melanoma was also observed when using a pH-sensitive liposome containing doxorubicin and deferasirox [93].”
BackgroundChen, J., Li, C., Cao, Y., Zhu, L., Zhang, B., You, J., Hou, H., Wang, J., & Yuan, Z. (2022) · BMC Cancer · doi:10.1186/s12885-022-09866-w · Cited by 12
Mohl, D. A., Lagies, S., Zodel, K., Zumkeller, M., Peighambari, A., Ganner, A., Plattner, D. A., Neumann‐Haefelin, E., Adlesic, M., Frew, I. J., et al. (2023) · Cells · doi:10.3390/cells12081102 · Cited by 12 · cited 1×
“About 75% of clear cell renal cell carcinomas display a loss of function of the VHL gene, which results from mutations, loss of heterozygosity, and promoter methylation [124,125].”
BackgroundAMOROSO, D., Bertelli, G., Pronzato, P., Vidili, M. G., Gulisano, M., Lionetto, R., & Rosso, R. (1989) · PubMed · Cited by 4
Cited by
Immunologic tumor microenvironment modulators for turning cold tumors hot
Khosravi, G., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · Cancer Communications · doi:10.1002/cac2.12539 · Cited by 364
“The constrained clinical advantages observed in a relatively minor proportion of patients can be attributed to various factors, chief among them being the dearth or restricted infiltration of immune cells within the microenvironment [183].”
BackgroundNanomaterials in the Wound Healing Process: New Insights and Advancements
Sangnim, T., Puri, V., Dheer, D., Venkatesh, D. N., Huanbutta, K., & Sharma, A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16030300 · Cited by 98
The future of affordable cancer immunotherapy
Schaft, N., Dörrie, J., Schuler, G., Schuler‐Thurner, B., Sallam, H., Klein, S., Eisenberg, G., Frankenburg, S., Lotem, M., & Khatib, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1248867 · Cited by 86
Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer
Din, S. M. U., Streit, S., Huynh, B. T., Hana, C. K., Abraham, A. N. J., & Hussein, A. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042060 · Cited by 69
“Moreover, HIF-1 α also has the capability of binding to the promoter of the PD-L1 gene, leading to the upregulation of this gene, further deactivating T cells and promoting the escape of the immune system in a manner that may lead to resistance against immune checkpoint inhibitors [32,34].”
BackgroundAbreu, M. M., Chocron, A. F., & Smadja, D. M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1487296 · Cited by 59
Metadata
- Authors
- Benoit, A., Vogin, G., Duhem, C., Berchem, G., & Janji, B.
- Affiliations
- Luxembourg Institute of Health (LU)
- Centre François Baclesse (LU)
- Centre Hospitalier de Luxembourg (LU)
- Corresponding author
- Janji, Bassam
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2023-07-05
- Volume
- 12
- Issue
- 13
- Pages
- 1787
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC10341162
- OpenAlex
- W4383375914
- Cited by
- 39
- References
- 149
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 11 · 2023: 5
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- FNRS Televie (7.4559.21 IMPACT21, 7.4560.21 INCITE21, BRIDGES2020/BM/15412275/SMART-COMBO, BRIDGES2021/BM/16358198/TRICK-ALDH, INTER/EUROSTARS21/16896480/C2I, INTER/EUROSTARS21/16896735/PreCyse)
- Roche Pharma 2023 (7.4559.21 IMPACT21, 7.4560.21 INCITE21, BRIDGES2020/BM/15412275/SMART-COMBO, BRIDGES2021/BM/16358198/TRICK-ALDH, INTER/EUROSTARS21/16896480/C2I, INTER/EUROSTARS21/16896735/PreCyse)
- RCMS foundation (INCOM BIOM) (7.4559.21 IMPACT21, 7.4560.21 INCITE21, BRIDGES2020/BM/15412275/SMART-COMBO, BRIDGES2021/BM/16358198/TRICK-ALDH, INTER/EUROSTARS21/16896480/C2I, INTER/EUROSTARS21/16896735/PreCyse)
- Luxembourg National Research Fund (7.4559.21 IMPACT21, 7.4560.21 INCITE21, BRIDGES2020/BM/15412275/SMART-COMBO, BRIDGES2021/BM/16358198/TRICK-ALDH, INTER/EUROSTARS21/16896480/C2I, INTER/EUROSTARS21/16896735/PreCyse)
- Kriibskrank Kanner Foundation, Luxembourg (2019) (7.4559.21 IMPACT21, 7.4560.21 INCITE21, BRIDGES2020/BM/15412275/SMART-COMBO, BRIDGES2021/BM/16358198/TRICK-ALDH, INTER/EUROSTARS21/16896480/C2I, INTER/EUROSTARS21/16896735/PreCyse)
- Action LIONS Vaincre le Cancer Luxembourg (7.4559.21 IMPACT21, 7.4560.21 INCITE21, BRIDGES2020/BM/15412275/SMART-COMBO, BRIDGES2021/BM/16358198/TRICK-ALDH, INTER/EUROSTARS21/16896480/C2I, INTER/EUROSTARS21/16896735/PreCyse)
- Stiftelsen Cancera (CombiN 2023) (7.4559.21 IMPACT21, 7.4560.21 INCITE21, BRIDGES2020/BM/15412275/SMART-COMBO, BRIDGES2021/BM/16358198/TRICK-ALDH, INTER/EUROSTARS21/16896480/C2I, INTER/EUROSTARS21/16896735/PreCyse)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- cold tumors, tumor microenvironment, cancer immunotherapy, immune checkpoint inhibitors, CTLA-4, PD-1/PD-L1 axis, tumor immune infiltration, tumor hypoxia, metabolic reprogramming, tumor reprogramming
- MeSH terms
- Immune Checkpoint Inhibitors, Humans, Immunotherapy, Neoplasms, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.